Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Factbox-Moderna sues Pfizer as patent owners fight over mRNA vaccine technology

Published 08/26/2022, 12:46 PM
Updated 08/26/2022, 12:51 PM
© Reuters. FILE PHOTO: Empty glass vials of Pfizer Inc's Pfizer/BioNTech COVID-19 vaccine ModernaTX, Inc's Moderna COVID vaccine are seen after being donated by Northwell Health to the collection of the Smithsonian's National Museum of American History in Washington
PFE
-
ALNY
-
ABUS
-
MRNA
-

(Reuters) - Pfizer (NYSE:PFE) /BioNTech and Moderna (NASDAQ:MRNA) have been hit with patent lawsuits by other companies related to their COVID-19 vaccines.

In the latest turn of events, the two mRNA vaccine makers are locking horns, with Moderna suing Pfizer and its German partner BioNTech for patent infringement in their race to develop the shot approved in the United States.

Moderna on Friday alleged that they copied a technology that it had developed years before the pandemic.

The following is a list of the lawsuits filed against these companies:

Company/companies Company/companies Date of lawsuit Details Lawsuit filed with

facing lawsuit filing lawsuit

Pfizer/BioNTech Moderna Aug. 26, 2022 Moderna alleges Pfizer/BioNTech, without permission, U.S. District Court in Massachusetts

copied mRNA technology that Moderna had patented between

2010 and 2016

Pfizer/BioNTech CureVac July 5, 2022 CureVac seeks compensation from Pfizer and BioNTech German Regional Court in Düsseldorf

without impeding the production, sale or distribution of

the vaccine.Pfizer and BioNTech in July seek judgment

from a U.S. court that they did not infringe the patents

held by CureVac. U.S. District Court in Massachusetts

Pfizer and Moderna Alnylam March 17, 2022 Alnylam Pharma (NASDAQ:ALNY) seeks damages over the use of its lipid Delaware federal court

Pharmaceuticals nanoparticle technology.

Moderna Arbutus Biopharma (NASDAQ:ABUS) Feb. 28, 2022 Arbutus and Genevant Sciences say they were not seeking Delaware federal court

Corp/ Genevant to block Moderna from producing or distributing the

Sciences vaccines, and asked for money damages including a

reasonable royalty on vaccine sales.

Pfizer's Canadian partner Acuitas Therapeutics in March Manhattan federal court

sues Arbutus, seeking to head off the patent infringement

lawsuit.

Pfizer/BioNTech Allele Biotechnology Oct. 5, 2020 Allele alleged PFE and BNTX used its patented fluorescent United States District Court, Southern District

© Reuters. FILE PHOTO: Empty glass vials of Pfizer Inc's Pfizer/BioNTech COVID-19 vaccine ModernaTX, Inc's Moderna COVID vaccine are seen after being donated by Northwell Health to the collection of the Smithsonian's National Museum of American History in Washington, U.S. March 4, 2021. Jaclyn Nash/National Museum of American History/Handout via REUTERS./File Photo

and Pharmaceuticals protein without permission in developing their vaccines. of California

The patent dispute was resolved in Jan. 2022. (https://reut.rs/3RbMW8H)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.